Nabi Biopharmaceuticals Names Dr. Raafat E.F. Fahim as President and Chief Executive...

Nabi Biopharmaceuticals Names Dr. Raafat E.F. Fahim as President and Chief
Executive Officer

ROCKVILLE, Md., Jan. 22, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals
(Nasdaq:NABI) today announced that the company's Board of Directors has named
Raafat E.F. Fahim, Ph.D. as President and Chief Executive Officer. Dr. Fahim,
who also joins the Board as a director, succeeds Leslie Hudson, Ph.D., who had
served as Interim President and Chief Executive Officer since February 2007. Dr.
Hudson will remain on the Board of Directors.

"The Board of Directors decision to tap Dr. Fahim was unanimous and we are
extremely pleased to have someone with Raafat's proven leadership qualities and
track record of success, particularly in the vaccines field, to lead Nabi," said
Geoffrey Cox, Ph.D., Chairman of the Board. "Raafat's extensive industry
experience and his knowledge and understanding of Nabi Biopharmaceuticals make
him the ideal candidate for this critical role."

Nabi Biopharmaceuticals has recently accomplished several key milestones that
provide a strong base for future value:

-- Obtaining positive final data from the NicVAX Phase 2b proof-of-
concept clinical trial in smoking cessation
-- Selling the Biologics strategic business unit for $185 mm to
Biotest Pharmaceuticals Corporation
-- Improving the financial position of the Company
-- Completing a strategic reorganization of the company resulting
in streamlined corporate structure and workforce
-- Initiating a $65 million common stock repurchase program.
"I am extremely excited to lead Nabi as President and CEO at this pivotal time,"
said Dr. Raafat Fahim. "We have strategically focused the company on its vaccine
pipeline and I am committed to working with the Board and our talented
management and development team to fully realize the value of our considerable
pipeline assets and to maximize shareholder value. Nabi's NicVAX and StaphVAX
vaccine programs have great potential to satisfy critical unmet medical need and
unlocking this value for our shareholders is my primary focus."

Dr. Fahim joined the Company in March 2003 as Vice President of Vaccine
Manufacturing Operations and was named Senior Vice President, Research,
Technical and Manufacturing Operations later that year. His most recent role was
Chief Operating Officer and General Manager of the Biologics Strategic Business
Unit. Prior to joining Nabi Biopharmaceuticals, Dr. Fahim spent the majority of
his career with Sanofi-Pasteur (previously Aventis Pasteur) where he was
instrumental in developing several vaccines from early research to approval and
commercialization. During his tenure he held positions of increasing importance
in R & D, late development and operations at Sanofi-Pasteur and spent the last 8
years of his tenure as Vice President, Industrial Operations. Dr. Fahim received
his Ph.D. in Biochemistry from the University of Toronto.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the
immune system to develop products that target serious medical conditions in the
areas of gram-positive bacterial infections and nicotine addiction. Nabi
Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate
Vaccine), an innovative and proprietary investigational vaccine for treatment of
nicotine addiction and prevention of smoking relapse, and StaphVAX(r)
(Staphylococcus aureus Vaccine), a vaccine designed to prevent the most
dangerous and prevalent strains of S. aureus bacterial infections. The company
is headquartered in Rockville, Maryland. For additional information about Nabi
Biopharmaceuticals, please visit our Web site:http://www.nabi.com.

Forward-Looking Statements

Statements in this release that are not strictly historical are forward-looking
statements including statements about the potential of our products in
development. You can identify these forward-looking statements because they
involve our expectations, beliefs, projections, anticipations or other
characterizations of future events or circumstances. These forward-looking
statements are not guarantees of future performance and are subject to risks and
uncertainties that may cause actual results to differ materially from those in
the forward-looking statements as a result of any number of factors. These
factors include, but are not limited to, risks relating to our ability to:
successfully pursue strategic and other alternatives; obtain successful clinical
trial results; receive PhosLo milestone and royalty proceeds; successfully
partner with third parties to fund, develop, and manufacture our pipeline
products, including NicVAX and our gram-positive infections products; realize
anticipated cost saving; attract and maintain the human and financial resources
to bring to market products in development; depend upon third parties to
manufacture our products; achieve approval and market acceptance of our
products; enter into and maintain arrangements with third parties to market and
sell our products; comply with reporting and payment obligations under
government rebate and pricing programs; raise additional capital on acceptable
terms, or at all; and re-pay our outstanding convertible senior notes when due.
Many of these factors are more fully discussed, as are other factors, in the
company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006
and our Quarterly Report on Form 10-Q for the quarter ended September 29, 2007
filed with the Securities and Exchange Commission.

-0-
CONTACT: Nabi Biopharmaceuticals
Investor Relations
301-770-3099
www.nabi.com